Aberrant IL-6-JAK-STAT3 signaling in cancer cells has emerged as a major mechanism for cancer initiation, development and progression [1] [2] [3] [4] [5] [6] [7] [8] [9] . In addition to mediating tumor cell proliferation and survival in a tumor cell-autonomous manner, IL-6-STAT3 signaling is crucial for inflammatory cell-mediated transformation and tumor progression 1, [6] [7] [8] 10, 11 . However, in normal physiology, IL-6-induced JAK-STAT3 signaling is tightly regulated, owing to the existence of negative feedback mechanisms 12, 13 . An unanswered question in the field is how STAT3 remains persistently activated in cancer, especially in tumor cells in which STAT3 activation is mainly driven by IL-6 and in tumor stromal nontransformed cells, such as myeloid cells, where IL-6-induced STAT3 activation has a key role for tumor initiation and progression. Although a constellation of growth factors and cytokines signal through STAT3, which could have synergistic effects on prolonging STAT3 activation, STAT3 activity in tumors induced by many growth factors and cytokines requires the IL-6-JAK2 signaling pathway 6 . This implies that growth factor and cytokine-induced STAT3 activation in tumors should also be transient. These observations collectively raise the possibility that there might be additional unidentified mediators or signaling pathways that are crucial for persistent activation of STAT3 in both tumor cells and tumor-associated immune cells.
An ideal model to study the crosstalk between tumor cells and tumor stromal cells is B16 tumors, which have relatively low Stat3 activity and IL-6 expression in cell culture but greatly enhanced Stat3 activity in vivo, achieved at least in part through IL-6 production by the tumor stromal immune cells 11, 14 . Our PCR-based microarrays using cDNAs prepared from B16 tumor-derived myeloid cells indicated that, among several known Stat3 downstream genes, including those encoding IL-6, IL-1β and vascular endothelial growth factor [15] [16] [17] , the gene with the largest difference in expression between Stat3 +/+ and Stat3 −/− tumor-derived myeloid cells was S1pr1, also known as Edg1 (Supplementary Table 1 ).
The S1PR1 gene encodes one of the G protein-coupled receptors for S1P, a biologically active metabolite of sphingolipid 18, 19 . S1P-S1PR1 plays a major role in lymphocyte egress and chemotaxis [20] [21] [22] [23] , cell proliferation and survival and tumor angiogenesis and metastasis [24] [25] [26] . However, it remains poorly defined at the molecular level how S1PR1 mediates such complex biological responses 18, 19 . Our findings here provide new insights into the downstream molecular events of S1P-S1PR1 signaling by identifying STAT3 as a direct regulator of S1PR1 expression in tumor and tumor-associated myeloid cells. Moreover, we characterize a positive feedback loop whereby S1PR1 elevation contributes to STAT3 activation, a mechanism that could support persistent STAT3 activation in tumors.
RESULTS

STAT3 regulates S1pr1 expression
As suggested by our microarray data (Supplementary Table 1), S1pr1 expression was elevated in tumor-derived myeloid cells relative to Interleukin-6 (IL-6)-Janus kinase (JAK) signaling is viewed as crucial for persistent signal transducer and activator of transcription-3 (STAT3) activation in cancer. However, IL-6-induced STAT3 activation is normally transient. Here we identify a key mechanism for persistent STAT3 activation in tumor cells and the tumor microenvironment. We show that expression of sphingosine-1-phosphate receptor-1 (S1PR1), a G protein-coupled receptor for the lysophospholipid sphingosine-1-phosphate (S1P), is elevated in STAT3-positive tumors. STAT3 is a transcription factor for the S1pr1 gene. Reciprocally, enhanced S1pr1 expression activates STAT3 and upregulates Il6 gene expression, thereby accelerating tumor growth and metastasis in a STAT3-dependent manner. Silencing S1pr1 in tumor cells or immune cells inhibits tumor STAT3 activity, tumor growth and metastasis. S1P-S1PR1-induced STAT3 activation is persistent, in contrast to transient STAT3 activation by IL-6. S1PR1 activates STAT3 in part by upregulating JAK2 tyrosine kinase activity. We show that STAT3-induced S1PR1 expression, as well as the S1P-S1PR1 pathway reciprocal regulation of STAT3 activity, is a major positive feedback loop for persistent STAT3 activation in cancer cells and the tumor microenvironment and for malignant progression.
normal splenic myeloid cells (Fig. 1a) . Targeted gene ablation of Stat3 in the myeloid compartment reduces tumor growth in vivo, and also decreases Stat3 activity 14, 27 in the tumor cells ( Supplementary  Fig. 1a) . Real-time PCR of various populations of tumor myeloid cells indicated that ablating Stat3 in myeloid cells also inhibited S1pr1 expression in this compartment (Fig. 1a) , Conversely, introducing a constitutively active Stat3 mutant, Stat3C 28 , into Stat3 −/− mouse embryonic fibroblast (MEF) cells increased S1pr1 expression (Fig. 1a) . Furthermore, B16 tumor cells growing in mice with Stat3 −/− myeloid cells showed reduced S1pr1 expression, at both the RNA and protein levels, compared to B16 tumor cells in mice with Stat3 +/+ myeloid cells (Fig. 1b) . However, expression of S1pr2 and S1pr3 was not upregulated by Stat3 in tumor-infiltrating immune cells or in tumors (Supplementary Fig. 1b) . This suggests that Stat3 activity regulates S1pr1 abundance in tumor and tumor-associated myeloid cells.
Immunohistochemical analyses indicated that expression of S1PR1 and phosphorylated STAT3 (p-STAT3) overlapped in diverse human tumor tissue types ( Fig. 1c and Supplementary Fig. 2a ). We performed H&E and p-STAT3 staining on the serial tissue sections to determine STAT3 activation in normal versus malignant areas (Fig. 1d) . The elevated expression of S1PR1 was confirmed in microdissected areas of human breast tissue sections comparing mostly malignant tumor cells versus those with mainly non-malignant cells by real-time RT-PCR (Fig. 1d) . We then used western blotting to confirm the correlation between STAT3 activity and S1PR1 expression in human breast cancer tissues (Fig. 1e) . The specificity of the S1PR1-specific antibody for western blotting was determined by probing lysates prepared from a human cancer cell line with or without knockdown of S1PR1 (Supplementary Fig. 2b) .
We next determined whether Stat3 might be a transcriptional activator of the S1pr1 gene. To upregulate Stat3 activity in NIH-3T3 fibroblasts, we transfected a vector encoding Stat3C or v-Src, which activates Stat3 (ref. 29) , or cotransfected vectors encoding v-Src and a dominant-negative mutant, Stat3D. We found that Stat3 activity modulated S1pr1 mRNA expression (Fig. 2a) . siRNA knockdown of Stat3 in B16 tumor cells also lowered S1pr1 mRNA levels (Fig. 2a) . We transfected MB49 tumor cells with a reporter vector encoding luciferase under control of the S1pr1 promoter (pGL3-S1pr1.WT). Concurrent expression of Stat3C with the S1pr1 reporter construct increased S1pr1 promoter activity, which was abrogated by mutation of the Stat3 DNA-binding site in the S1pr1 promoter (positioned at −588 base pairs; pGL3-S1pr1.Mut) or by co-transfection with Stat3-targeting siRNA (Fig. 2b) . The inhibitory effect of Stat3 siRNA on S1pr1 promoter activity was further shown in B16 tumor cells (Fig. 2b) . We next carried out chromatin immunoprecipitation (ChIP) assays to assess whether Stat3 directly binds the S1pr1 promoter. Stat3 protein bound the S1pr1 promoter in lysates prepared from tissues of B16 tumors grown in vivo (Fig. 2c) . We repeated the ChIP assays with lysates prepared from cultured B16 tumor cells treated with conditioned medium supplemented with C-4 melanoma tumor cell supernatant, which induces Stat3 activation 14 . Stat3 knockdown by siRNA abrogated Stat3 binding to the S1pr1 promoter and reduced association of acetylated histone H4 with the promoter, indicating the requirement of Stat3 for S1pr1 promoter activity (Fig. 2c) . Furthermore, STAT DNA-binding activity to the S1PR1 promoter in human tumor cells of T cell origin correlated with STAT3 activity (Supplementary Fig. 3 ).
S1pr1 signaling in tumor cells promotes tumor progression
Silencing S1pr1 in tumor endothelial cells by siRNA and neutralizing S1P with an antibody in mouse tumor models have been shown to inhibit tumor growth 24, 26 . Whether elevated S1pr1 expression in tumor cells directly promotes tumor growth and which S1P receptor expressed in what type of cells in the tumor microenvironment mediates S1P tumor-promoting effects have not been assessed. To assess a potential role of S1pr1 in tumor cells in promoting tumor growth and metastasis, we increased endogenous S1pr1 expression in MB49 mouse bladder tumor cells by transfecting a doublestranded 21-mer RNA complementary to the S1pr1 promoter that can increase endogenous S1pr1 expression ( Supplementary Fig. 4a ).
The ability of certain double-stranded short RNAs (dsRNAs) derived from promoter regions that specifically activate gene expression has been previously described 30 . MB49 tumors do not grow progressively in female mice because these tumor cells express a male antigen 31 . Increasing endogenous S1pr1 expression in tumor cells by the dsRNA allowed the tumors to grow progressively in both female and male mice ( Fig. 3a and Supplementary Fig. 4b ). To confirm the ability of elevated expression of endogenous S1pr1 to enhance tumor growth, we tested whether ectopic expression of S1PR1 in tumor cells could also increase tumor growth by transiently transfecting into MB49 tumor cells a plasmid vector expressing the human S1PR1 gene, which led to increased S1PR1 expression (Fig. 3a) . We then challenged mice with both control and S1PR1-expressing MB49 tumor cells. The results from these experiments confirmed that increasing S1PR1 expression in tumor cells promotes both tumor growth and metastasis (Fig. 3) . We also confirmed the tumor-promoting effects of S1PR1 in the B16 tumor model (Supplementary Fig. 4c ).
Analysis of MB49 tumors showed that enhancing S1pr1 expression increased S1pr1 abundance at both the RNA and the protein levels, which led to an increase in p-Stat3 levels (Fig. 3b) . To confirm that S1pr1 expression affects Stat3 activity in tumor cells, we performed the converse experiment by transfecting MB49 tumor cells with siRNA to silence S1pr1, which inhibited Stat3 activity (Fig. 3b) . Furthermore, enhancing S1pr1 expression in MB49 tumors increased the mRNA abundance of several well-established Stat3 downstream genes (Fig. 3c) . Taken together, these results support a role for increased S1PR1 expression in tumor cells in enhancing Stat3 activity in an autocrine manner.
Tumor cell S1pr1 affects Stat3 in stromal cells
To determine whether Stat3 activation induced by increased S1pr1 expression in tumor cells also affected Stat3 activity in tumor stromal cells, we examined S1pr1 and p-Stat3 abundance in myeloid cells isolated from MB49 tumors formed by transplanting tumor cells with or without increased S1PR1 expression. CD11b + myeloid cells derived from tumors with increased S1PR1 expression had higher amounts of both S1pr1 and p-Stat3 as compared to myeloid cells derived from tumors consisting of tumor cells transfected with control empty vector (Fig. 4a) .
We further tested the in vivo finding that S1pr1 expression could 'propagate' from tumor cells to interacting myeloid cells in vitro by coculturing various myeloid cell populations with both tumor cells and tumor-conditioned supernatants. Data from these experiments indicated that coculturing both CD11b + and CD11b − (CD11b-depleted) myeloid cells with tumor cells expressing S1pr1 increased myeloid cell S1pr1 expression and Stat3 activity (Fig. 4a) . When cultured in the presence of 10% tumor supernatant prepared from S1PR1-expressing MB49 tumor cells, Gr1 + myeloid cells also showed enhanced S1pr1 expression and Stat3 activity (Fig. 4a) . We further determined whether the propagation of S1pr1 upregulation from tumor cells to myeloid cells was Stat3 dependent. The S1pr1-overexpressing tumor supernatant was able to upregulate S1pr1 expression in Stat3 +/+ but not in Stat3 −/− myeloid cells (Fig. 4b) . These results suggest that the reciprocal regulation of S1PR1-STAT3 mediates a crosstalk between tumor cells and various myeloid cells.
We next evaluated potential factors involved in mediating S1pr1-induced Stat3 activation from tumor cells to the tumor stromal myeloid cells. Because IL-6 is an essential physiological STAT3 activator that also drives STAT3-mediated oncogenesis, and given that STAT3 activation increases IL-6 expression in tumors, especially tumor-associated immune cells 4, 15, 32, 33 , we examined whether increasing S1PR1 expression in tumor cells would lead to Stat3-mediated production of factors that could affect IL-6 expression in mouse myeloid cells in vitro. Tumor supernatants from S1PR1-expressing MB49 tumor cells not only increased S1pr1 but also enhanced Il6 expression in myeloid cells, both of which were also Stat3 dependent (Fig. 4c) . ELISA confirmed increased concentrations of IL-6 in tumors with S1PR1 overexpression (Fig. 4d) . Adding IL-6-neutralizing antibody to ex vivo culture of B16 tumors reduced S1pr1 and p-Stat3 abundance (Fig. 4d) , indicating that IL-6 is a major mediator of S1pr1-Stat3 signaling.
We also assessed S1pr1-Stat3 reciprocal regulation and Il6 RNA expression in myeloid cells in the tumor milieu. Upon incubation with conditioned medium from MB49 tumors, p-Stat3, S1pr1 and Il6 RNA expression was induced in S1pr1 +/+ but not S1pr1 −/− myeloid cells (Supplementary Fig. 5a ). Ex vivo treatment of tumor-infiltrating immune cells with the S1PR1 antagonist, W146, inhibited Stat3 activity (Supplementary Fig. 5b ). To determine whether S1pr1-mediated tumorigenesis in vivo depends on Stat3 activity in myeloid cells, we implanted control and S1PR1-expressing MB49 tumor cells subcutaneously into mice with Stat3 +/+ or Stat3 −/− hematopoietic cells. Without Stat3 in hematopoietic cells, elevated S1PR1 expression in tumor cells failed to promote tumor growth (Fig. 4e) . Taken together, these data suggest that the reciprocal regulation of S1pr1 and Stat3 provides a crosstalk between tumor cells and their microenvironment that contributes to tumor growth. 
S1pr1-mediated Stat3 activation is persistent
Further characterization of S1PR1 expression effects on Stat3 DNAbinding activity by electrophoretic mobility shift assay (EMSA) showed that increasing S1PR1 expression led to increased Stat3 activity without additional stimuli (Fig. 5a) . Adding the S1PR1 antagonist W146 into cultured S1PR1-expressing MB49 tumor cells abolished Stat3 activity (Fig. 5b) . We also examined whether S1P-induced S1PR1 signaling activates Stat3. Endothelial cells are known to express S1pr1 and respond to S1P 26 . After treatment with S1P, cells from an immortalized mouse prostate endothelial cell line, which has low but detectable endogenous Stat3 activity 17 and low S1pr1 expression, showed an induction of Stat3 activation (Supplementary Fig. 6a ). Increasing endogenous S1pr1 expression by treating the cells with the S1pr1 agonist SEW2871 also increased p-Stat3 amounts in MB49 tumor cells (Fig. 5b) . S1P-induced Stat3 activation was more pronounced in the S1PR1-expressing tumor cells than in their counterparts without elevated S1PR1 expression (Supplementary Fig. 6a ).
To further characterize the effects of S1P and S1PR1 versus IL-6 on Stat3 activation, we treated S1pr1 +/+ and S1pr1 −/− myeloid cells with either IL-6 or S1P, which activates not only S1pr1 but also other S1P receptors. Stat3 activation was induced as early as 20 min after S1P treatment and lasted over 18 h, whereas IL-6-induced Stat3 activation was short-lived (Fig. 5c) . Similarly, treating MB49 tumor cells with IL-6 resulted in transient Stat3 activation. Stimulating the tumor cell with a S1pr1-selective ligand, SEW2871, led to prolonged Stat3 activation (Fig. 5c) . In addition, ablating S1pr1 in splenocytes or knocking down S1pr1 in tumor cells did not affect IL-6-induced Stat3 activation, whereas prolonged Stat3 activation mediated by the S1PR1 agonists S1P and SEW2871 was absent in cells lacking S1pr1 (Fig. 5c) . These results indicate that S1P-S1PR1 signaling can induce persistent STAT3 activation.
S1pr1-induced Stat3 activity involves Jak2 kinase
To explore whether Jak2 and Src tyrosine kinases are involved in S1PR1 or S1P-S1PR1-mediated Stat3 activation, we performed immunoprecipitation with a hemagglutinin (HA)-specific antibody to collect HA-tagged S1PR1 in MB49 tumor cells, followed by western blot analysis. We detected a S1PR1-Jak2 interaction, which was confirmed by the converse immunoprecipitation with a Jak2-specific antibody (Fig. 5d) . Src tyrosine kinase, a known Jak2 binding partner, also interacted with S1PR1, as shown by immunoprecipitation with Src-specific antibody followed by western blot analysis ( Fig. 5d  and Supplementary Fig. 6b ). In addition, immunoprecipitated Jak2 protein from S1P-stimulated, S1PR1-expressing MB49 tumor cells had increased kinase activity relative to empty vector-transfected control tumor cells, as measured by tyrosyl phosphorylation of recombinant Stat3 protein in vitro (Fig. 5d) . Furthermore, an ELISA-based Jak2 phosphokinase assay showed that co-culturing MB49 and B16 tumor cells with supernatant collected from S1PR1-expressing tumor cells increased Jak2 kinase activity, which we also observed with splenocytes (Fig. 5e) . Blocking Jak2 kinase activity with the Jak2 inhibitor AZD1480 (ref. 9) abrogated S1PR1-mediated Stat3 activation in MB49 tumor cells (Fig. 5f) . Jak2 activity was also upregulated in tumors harboring elevated S1PR1 (Fig. 5g) . To test whether increasing S1PR1 expression in myeloid cells would elevate Jak2 activity in tumors in vivo, we implanted into mice parental tumor cells mixed with either control vector-or S1PR1-expressing CD11b + myeloid cells. Analysis of Jak2 activity in the tumor tissues containing the myeloid cells showed that increasing S1PR1 expression in myeloid cells enhanced Jak2 kinase activity in tumors (Fig. 5g) . These data suggest that increasing S1PR1 can activate JAK2, leading to STAT3 activation. To further confirm that S1PR1 induces JAK2-STAT3 activation, we silenced Gα i , Gα o and Gα q proteins with specific siRNAs in tumor cells overexpressing S1PR1. Consistent with previous findings indicating a requirement for Gα i and Gα o in the S1P-S1PR1 signaling pathway 34 , and supporting our finding that S1PR1 induces Jak2-Stat3 activation, inhibition of Gα i or Gα o decreased Stat3 activation and p-Jak2 amounts induced by S1PR1 expression in tumor cells (Fig. 5h) .
In the case of IL-6 stimulation, JAK2 activation induces STAT3-mediated SOCS3 gene expression, which, in turn, inhibits JAK2-STAT3 signaling. We tested whether S1PR1-induced persistent STAT3 activation also upregulates SOCS3 expression. In S1PR1-expressing MB49 tumors, SOCS3 mRNA was not elevated but was instead repressed (Supplementary Fig. 7a ). We then examined whether S1PR1 downregulates SOCS3 transcriptional activity by transfecting a SOCS3 promoter-luciferase construct into MB49 tumor cells together with either pcDNA (control) plasmid or the HA-S1PR1-expressing plasmid. Increased S1PR1 expression reduced SOCS3 promoter activity (Supplementary Fig. 7b) . Conversely, blocking S1pr1 by siRNA further enhanced SOCS3 promoter activity in MB49 cells compared to cells expressing control siRNA CpG-Luc siRNA CpG-S1pr1 siRNA ( Supplementary Fig. 7b ). IL-6-induced SOCS3 promoter activity was not altered by S1pr1 silencing (Supplementary Fig. 7b ).
Targeting S1pr1 in tumor and stroma for cancer therapy We next assessed whether targeting S1PR1 signaling in either tumor cells or stromal myeloid cells could inhibit Stat3 activity, tumor growth and metastasis. To test whether S1pr1 in tumor cells could serve as a target for cancer therapy, we implanted into mice MB49 tumor cells stably expressing S1pr1-targeting shRNA. Tumor growth, as well as p-Stat3 and S1pr1 expression, was significantly inhibited in tumor and tumor-infiltrating immune cells (Fig. 6a) , suggesting that targeting S1pr1 in tumor cells can inhibit tumor Stat3 activity and tumor growth.
To evaluate whether S1pr1 in myeloid cells is also a molecular target to inhibit Stat3 activity for cancer therapy, we injected B16 tumor cells into mice with control and S1pr1-deficient myeloid cells. Results from this set of experiments showed that lack of S1pr1 expression in myeloid cells led to a marked decrease in tumor growth and Stat3 activity (Fig. 6b) . This is consistent with previous studies reporting that ablating Stat3 in myeloid cells affected Stat3 activity in the whole tumor 14 , including tumor cells (Supplementary Fig. 1a) . Knockout of S1pr1 in hematopoietic cells also significantly decreased lung metastasis (Fig. 6c) . Furthermore, we used an in vivo siRNA delivery approach that links siRNA to a short single-stranded CpG oligonucleotide 35 . CpG is a ligand for endosomal Toll-like receptor 9, which is mainly expressed in myeloid cells and B cells. Treating mice with established MB49 tumors or B16 tumors with CpG-S1pr1 siRNA conjugate inhibited tumor growth and metastasis, tumor Stat3 activity and expression of many STAT3 target genes (Fig. 6d,e and Supplementary Fig. 8 ). Taken together, these results suggest that inhibiting S1pr1 expression in either tumor cells or stromal myeloid cells decreases Stat3 activity in tumors and reduces tumor growth.
DISCUSSION
Our study has identified a mechanism that facilitates persistent STAT3 activation in cancer, at least in the setting where IL-6-gp130-JAK signaling is the driving force, which is crucial for cancer initiation and progression as well as many inflammatory diseases. We show here that S1PR1 expression is elevated in both mouse and human tumors that show persistent STAT3 activity and also that STAT3 binds to the S1pr1 gene promoter. STAT3-mediated S1PR1 upregulation, facilitated by S1P and IL-6, contributes to persistent STAT3 activity in both tumor cells and the tumor microenvironment, thereby promoting malignant progression (Fig. 6f) .
Although the key role of persistent JAK2 activation in cancer has become increasingly evident 9, 36 , the underlying mechanisms of continuous JAK2 activation in the tumor microenvironment remain to be further explored. Our findings demonstrate that S1PR1, a G protein-coupled receptor, is capable of activating STAT3, at least in part, through the JAK2 tyrosine kinase. Even though overexpressing a constitutively activated mutant of Gα subunit, Q205L Gα o protein, in fibroblasts can activate STAT3 through Src kinase 37 , we show that Gα i and Gα o are partly required for S1P-S1PR1 induction of STAT3 in tumors, in part through S1PR1-mediated JAK2 activation. Src could also contribute to S1PR1-induced STAT3 activation, either directly or indirectly through interacting with JAK2.
We show that S1P-S1PR1 signaling induces persistent STAT3 activation, which is in sharp contrast to the transient nature of STAT3 activation induced by IL-6. Although maintained at low levels in most tissues, S1P abundance increases under inflammatory conditions and in the tumor microenvironment 24, 38 . Whether STAT3 activity regulates S1P remains to be determined. Nevertheless, the specificity and activity of S1P-S1PR1 signaling, which has diverse biological consequences, is in part determined by S1PR1 abundance 19, 21, 39 . By virtue of its ability to directly upregulate S1PR1 expression, Stat3, whose activity is modulated by defined cytokines and growth factors, can affect which cells, and when, respond to S1P. S1PR1 is crucial for lymphocyte egress [20] [21] [22] . It also inhibits T helper type 1 (T H 1) cell cytokines, such as interferon-γ and IL-12, and promotes the release of T H 2, including IL-10, and T H 17 cell cytokines 18, 19, 40 . The role of STAT3 in regulating immune responses in many ways overlaps with that of S1PR1 (ref. 4) . STAT3 is also crucial for angiogenesis, not only for the production of multiple key angiogenic factors but also for their receptor signaling [3] [4] [5] . Linking S1PR1 with STAT3 signaling thus suggests that S1PR1-mediated immune modulation and angiogenesis is at least in part mediated by STAT3. Many cytokines and growth factors, such as vascular endothelial growth factor, epidermal growth factor and platelet-derived growth factor, known to interact with S1P-S1PR1 signaling 41 , are also STAT3 activators, and STAT3 in turn promotes their production. Our findings thus link STAT3 signaling directly with the S1P-S1PR1 axis. Their co-regulation in both tumor cells and tumor stromal cells may have profound biological and therapeutic implications for cancer and other inflammatory diseases. 
METHODS
Methods
ONLINE METHODS
In vivo tumor experiments. Mouse care and experimental procedures were carried out under pathogen-free conditions in accordance with established institutional guidance and approved protocols from the Institutional Animal Care and Use Committee of Beckman Research Institute at City of Hope Medical Center. The generation of Stat3 +/+ and Stat3 −/− mice has been previously described 27 . For mice with S1pr1 ablation in hematopoietic cells, we crossed S1pr1 flox/flox mice with Mx1-Cre mice. The Mxl promoter responds to IFN or poly(I:C) treatment, allowing the expression of Cre protein to carry out targeted gene ablation in hematopoietic cells.
For subcutaneous MB49 tumor challenge, we injected tumor cells subcutaneously into the flank of female C57BL/6 mice 24 h after transfection with either dsRNA complementary to mouse S1pr1 promoter or plasmid encoding HA-tagged S1PR1.
For the experimental lung metastasis model, we injected B16 tumor cells intravenously into S1pr1 +/+ or S1pr1 −/− mice. After 21 d, the number of visible metastatic tumor nodules was determined in the lung by counting individual nodules.
We killed mice 1 d after the last tumor measurement in all cases. The detailed methods and sequence for S1pr1 dsRNA and CpG-conjugated siRNA are provided in the Supplementary Methods.
Isolation of immune cells. Purification of specific immune subsets and generation of tumor supernatant has been previously described 14, 27 , and details are provided in the Supplementary Methods. Sources of human tissues and RNA and protein preparations. We obtained human tissue array slides from the archive of City of Hope Medical Center Pathology Core and optimal cutting temperature medium (OCT)-embedded frozen human breast tumor tissue sections from the Translational Research Core at City of Hope Medical Center, with Institutional Review Board approval. Additional normal and tumor OCT-embedded frozen human breast tissue sections were also purchased from OriGene.
To isolate total RNA from frozen breast tissue sections, we placed the slides on a light microscope, and, while viewing, we gently scraped patches with mostly either tumor cells or nonmalignant cells (confirmed by H&E staining of consecutive sections) with a 27.5-gauge needle. The tip of the needle was placed into a tube containing lysis buffer for RNA isolation (RNAqueous-Micro kit, Ambion). We used ten consecutive slides for each RNA preparation.
To extract proteins from human breast cancer tissues, OCT-embedded frozen tissue slides were dried at room temperature (25 °C for 30 min). Tissues were scraped from the slide and transferred into a tube containing modified RIPA buffer described in the Supplementary Methods, vortexed briefly, sonicated twice and then subjected to three cycles of freezingthawing in dry ice. After centrifugation, supernatants were collected and stored at −80 °C. Five consecutive tissue sections were pooled together for one experiment.
Real-time reverse transcription PCR. Total RNA preparation (mouse tissue or cell lines) and real-time PCR were performed as previously described 35 , and details are provided in the Supplementary Methods.
For PCR-based gene profiling in B16 tumor-infiltrating CD11b + myeloid cells, we purchased an array plate from SA Bioscience. Data were analyzed according to the manufacturer's instructions.
Immunohistochemical and immunofluorescent staining and confocal microscopy. Immunohistochemical staining of OCT-embedded frozen tissue slides was performed as described in the Supplementary Methods.
Immunofluorescent staining and confocal microscopy were performed as previously described 14 , and detailed experimental procedures are also provided in the Supplementary Methods.
